Last reviewed: May 31, 2026
Last updated: May 31, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Methylene blue costs between $20 and $150 monthly, depending on formulation, dosage, and clinical indication. This oral or intravenous agent has niche applications in conditions ranging from urinary tract infection prevention to emerging cognitive research, yet cost alone does not determine clinical appropriateness.
Beyond price, the decision to use methylene blue should rest on clinical evidence, your individual health markers, and provider assessment of therapeutic benefit. PlexusDx's precision-wellness model emphasizes understanding your unique metabolic and genetic context—factors that can inform whether this or alternative approaches align best with your goals.
Methylene Blue Formulations and Their Cost Range
Methylene blue is available in multiple formulations: oral tablets (typically 65–100 mg), injectable solutions, and compounded preparations. Oral tablets from retail pharmacies often cost $25–$75 monthly for standard dosing. Injectable forms used in clinical settings range from $50–$150 per administration depending on hospital markup and setting.
Compounded methylene blue preparations may offer cost flexibility but require evaluation of pharmacy licensing (503A compounding) and clinical appropriateness. Retail pricing varies significantly based on insurance coverage, mail-order versus in-store dispensing, and whether the medication is used off-label for conditions beyond FDA-approved indications.
Clinical Indications and Evidence-Based Cost Justification
Methylene blue's primary FDA-approved use is treating methemoglobinemia. Off-label applications—including UTI prevention, cognitive support in aging, and mitochondrial function enhancement—have emerging research but lack definitive guideline recommendations. Cost justification should align with clinical evidence specific to your condition.
| Clinical Indication |
Evidence Level |
Typical Dosage |
Estimated Monthly Cost |
| Methemoglobinemia (FDA-approved) |
Strong (acute treatment) |
1–2 mg/kg IV once |
$50–$150 per dose |
| Urinary tract infection prevention |
Moderate (limited trials) |
50–100 mg daily oral |
$25–$60 |
| Cognitive/mitochondrial support (off-label) |
Emerging (preliminary studies) |
50–100 mg daily oral |
$30–$75 |
| Sepsis adjunctive therapy (investigational) |
Weak (case reports) |
Variable |
$40–$120 |
Insurance Coverage, Accessibility, and Hidden Costs
Most insurance plans do not routinely cover methylene blue for off-label indications. Coverage is typically limited to acute methemoglobinemia treatment in clinical settings. Out-of-pocket costs escalate when used for preventive or investigational purposes, making transparency with your pharmacy and insurer essential before initiating therapy.
Hidden costs include consultation fees for providers unfamiliar with methylene blue protocols, potential drug-interaction testing, and monitoring labs if used chronically. Generic oral formulations are generally affordable ($20–$40 monthly), but specialty compounded versions or IV preparations significantly increase expense without guaranteed improved outcomes.
Safety Profile, Biomarker Context, and Provider Oversight
Methylene blue carries important safety considerations: it inhibits monoamine oxidase (MAO), risking serotonin syndrome if combined with SSRIs or MAOIs. It can cause hemolysis in individuals with G6PD deficiency—a genetic variant that should be screened before use. High doses may cause dysuria and blue discoloration of urine and skin, which are benign but important to expect.
Before pursuing methylene blue therapy, discuss with your provider whether your genetic or metabolic context increases risk or benefit. Biomarker evaluation—including G6PD status, serotonergic medication interactions, and kidney function—helps determine whether this treatment is appropriate and cost-effective for your situation.
How PlexusDx Supports a More Personalized Approach
While methylene blue addresses specific clinical needs, PlexusDx's Precision Peptide Genetic Test may help provide context about your underlying metabolic pathways and genetic predispositions. Understanding whether your biology favors mitochondrial-support therapies or metabolic optimization through other channels can support a more personalized cost-benefit conversation with your provider.
The test reveals predispositions in metabolic and peptide-related genetic variants (including FTO rs9939609, MC4R rs17782313, and others). These insights do not predict exact methylene blue response, but they can inform your provider's broader assessment of whether this therapy aligns with your individual health needs and whether alternative precision approaches might offer greater benefit.
If you're considering methylene blue for metabolic support or cognitive enhancement, PlexusDx recommends discussing your genetic context and biomarker profile with a qualified healthcare provider. This conversation can help ensure your treatment choices—and associated costs—are grounded in evidence and tailored to your unique physiology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the typical monthly cost of methylene blue for off-label use?
Oral methylene blue from retail pharmacies typically costs $20–$75 monthly for standard preventive or cognitive-support dosing. Compounded preparations and injectable formulations may cost more. Always verify coverage with your insurance, as off-label uses are rarely covered.
Is methylene blue FDA-approved for all its common uses?
No. Methylene blue is FDA-approved only for acute methemoglobinemia treatment. Cognitive support, UTI prevention, and mitochondrial-enhancement uses are off-label and supported by limited or preliminary research. Your provider should discuss evidence and risk-benefit ratios before recommending off-label use.
How does genetic testing relate to methylene blue safety?
G6PD deficiency—detected through genetic screening—increases hemolysis risk with methylene blue. PlexusDx's Precision Peptide Genetic Test includes metabolic predisposition markers that may help your provider contextualize whether methylene blue or alternative approaches better suit your biology and goals.
What are the main side effects and safety concerns?
Methylene blue can cause serotonin syndrome if combined with SSRIs or MAOIs, hemolysis in G6PD-deficient individuals, dysuria, and blue urine or skin discoloration. High doses carry additional risks. Discuss all medications and genetic history with your provider before starting.
Should I choose methylene blue based solely on cost?
No. Cost should factor into your decision, but clinical evidence, your individual health markers, and provider assessment of therapeutic benefit are equally important. PlexusDx emphasizes understanding your genetic and biomarker context to help ensure treatment choices align with your long-term health priorities.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where To Inject MIC B12: Clinical Placement & Biomarker Context
What Is Lipo Pure Mic B12: Mechanism, Biomarkers, and Clinical Context